注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Astria Therapeutics Inc是一家生物制药公司,专注于发现、开发和商业化治疗受罕见和特殊过敏性和免疫性疾病影响的患者和家庭。该公司的主要候选产品是STAR-0215,其为一种潜在的血浆激肽释放酶单克隆抗体抑制剂,用于治疗遗传性血管水肿(HAE)。遗传性血管水肿是一种罕见的遗传性疾病,其特征是面部、四肢、腹部和气道出现严重、复发、不可预测、疼痛,有时甚至危及生命的肿胀。STAR-0215是血浆激肽释放酶的单克隆抗体抑制剂,旨在为遗传性血管水肿提供长效预防。该公司的遗传性血管水肿治疗按需治疗包括BERINERT、Firazr、KALBITOR和RUCONEST。其遗传性血管水肿治疗的长期预防性治疗包括CINRYZE、HAEGARDA、TAKHZYRO和ORLADEYO。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Kenneth M. Bate | 73 | 2014 | Independent Chairman of the Board |
Jill C. Milne | 55 | 2008 | Co-Founder, CEO, President & Director |
Jonathan Violin | 48 | 2021 | Independent Director |
Hugh M. Cole | 58 | 2019 | Independent Director |
Frederick Peter Callori | 55 | 2021 | Independent Director |
Gregory Anthony Lapointe | 64 | 2019 | Independent Director |
Jay D. Horton | - | - | Member of Scientific Advisory Board |
Joanne T. Beck | 61 | 2019 | Independent Director |
Johannes Jacob Pieter Kastelein | 69 | - | Member of Scientific Advisory Board |
Steven E. Shoelson | - | - | Member of Scientific Advisory Board |
Roger Ulrich | - | - | Member of Scientific Advisory Board |
Michael Jirousek | 64 | 2008 | Member of Scientific Advisory Board |
Sekar Kathiresan | 51 | - | Member of Scientific Advisory Board |
Edward M. Scolnick | 82 | - | Member of Scientific Advisory Board |
Michael D. Kishbauch | 74 | 2016 | Independent Director |
Arthur H. Rubenstein | 86 | - | Member of Scientific Advisory Board |
Sunil Agarwal | 54 | 2024 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核